4C Medical Releases Global Clinical Data at AATS 2022

Shanghai, China, 17 June 2022 – MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”) announced that its strategic partner, 4C Medical Technologies, Inc. (“4C Medical”) recently presented global clinical experience and data on the early feasibility study (EFS) of its innovative transcatheter mitral valve implant replacement (TMVR), AltaValve™, at the Mitral Valve Symposium of American Association for Thoracic Surgery (AATS) in Boston on May 13, 2022.

With a unique supra-annular valve device and atrial fixation design, AltaValve™ expands the number of patients who can benefit from transcatheter mitral valve replacement. AltaValve™ EFS results show 100% technical success for the first 10 patients treated worldwide via the transapical approach. In all cases, the degree of MR decreased from severe to no or minimal regurgitation and was maintained throughout long-term follow-up.

Dr. Krzysztof Wrobel, a cardiac surgeon at Medicover Hospital in Warsaw, Poland, presented his clinical experience with AltaValve™ at AATS 2022: "Based on our initial clinical experience, the AltaValve™ transapical approach procedure is simple and easy to perform, with clinically significant reduction in mitral regurgitation. The long-term follow-up results of AltaValve™ are very encouraging, and no thrombosis or erosion of the implant, permanent pacemaker implantation or other device-related problems have been observed in this cohort of patients. We are collecting additional clinical data, including transseptal access cases, to further build on this experience."

In 2018, CardioFlow Medtech acquired an exclusive interest in 4C Medical's mitral valve technology in China through series A financing. In 2021, CardioFlow Medtech made an additional investment to become its largest shareholder and also acquired exclusive commercial rights in China for 4C Medical's tricuspid valve products under development. As a result, CardioFlow Medtech has further diversified its product line to form a more complete and diverse portfolio.

About 4C Medical

4C Medical Technologies, Inc, is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. Subject to regulatory approvals, the Company’s AltaValve™ would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which rely on placement and fixation within the native mitral annulus.

About CardioFlow Medtech

MicroPort CardioFlow Medtech Corporation is a leading medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart diseases. On February 2021, The Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited (Stock Code: 02160.HK), the Company’s self-developed first-generation Transcatheter Aortic Valve Implantation (TAVI) product, with its unique product design and outstanding clinical performance, has entered more than 300 hospitals across China and was successfully commercialized in Argentina. The Company’s second-generation TAVI product VitaFlow Liberty™ also the world’s only commercialized motorized retrievable system was approved by the NMPA in August 2021. In addition to the TAVI products, the company has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies, surgical valve products and surgical accessories via independent development and collaboration with global partners.